Taysha Gene Therapies, Inc. (TSHA) · INSIDERData sourcesSEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago
Public companyTaysha Gene Therapies, Inc.
TSHACIK 0001806310
Price$4.37
1 year+11.5%
Disclosed transactions18
Buys / sells0 / 6
Max Insider Score36
Connections with evidence5
TSHA · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 0 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Option exercise · 10b5-1 plan | M | $33K 19.0K sh | Apr 10, 2026 |
| Apr 13, 2026 traded Apr 10, 2026 |
| 0 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Option exercise · 10b5-1 plan | M | — 19.0K sh | Apr 10, 2026 | Apr 13, 2026 traded Apr 10, 2026 | +3d | SEC Form 4 | |
| 11 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Open-market sale · 10b5-1 plan | SELL | $892K 200.0K sh | Apr 10, 2026 | Apr 13, 2026 traded Apr 10, 2026 | +3d | SEC Form 4 | |
| 25 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Open-market sale | SELL | $124K 26.9K sh | Jan 26, 2026 | Jan 27, 2026 traded Jan 26, 2026 | +1d | SEC Form 4 | |
| 32 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Open-market sale | SELL | $423K 89.1K sh | Jan 23, 2026 | Jan 27, 2026 traded Jan 23, 2026 | +4d | SEC Form 4 | |
| 25 | AKAlam KamranCHIEF FINANCIAL OFFICER | TSHATaysha Gene Therapies, Inc. Open-market sale | SELL | $110K 23.8K sh | Jan 26, 2026 | Jan 27, 2026 traded Jan 26, 2026 | +1d | SEC Form 4 | |
| 36 | AKAlam KamranCHIEF FINANCIAL OFFICER | TSHATaysha Gene Therapies, Inc. Open-market sale | SELL | $375K 79.0K sh | Jan 23, 2026 | Jan 27, 2026 traded Jan 23, 2026 | +4d | SEC Form 4 | |
| 6 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Option exercise · 10b5-1 plan | M | $152K 88.7K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 20 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Open-market sale · 10b5-1 plan | SELL | $942K 200.0K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 7 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Grant or award · 10b5-1 plan | A | — 427.0K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 11 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Option exercise · 10b5-1 plan | M | — 111.3K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 7 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Option exercise · 10b5-1 plan | M | — 88.7K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 0 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Grant or award · 10b5-1 plan | A | — 274.0K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 9 | NPNolan Sean P.Director, Chief Executive Officer | TSHATaysha Gene Therapies, Inc. Grant or award | A | — 648.0K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 17 | AKAlam KamranCHIEF FINANCIAL OFFICER | TSHATaysha Gene Therapies, Inc. Grant or award | A | — 359.0K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 17 | NPNolan Sean P.Director, Chief Executive Officer | TSHATaysha Gene Therapies, Inc. Grant or award | A | — 1.01M sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 9 | AKAlam KamranCHIEF FINANCIAL OFFICER | TSHATaysha Gene Therapies, Inc. Grant or award | A | — 231.0K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
| 6 | NSNagendran SukumarDirector, President and Head of R&D | TSHATaysha Gene Therapies, Inc. Option exercise · 10b5-1 plan | M | $78K 111.3K sh | Jan 12, 2026 | Jan 14, 2026 traded Jan 12, 2026 | +2d | SEC Form 4 | |
Director, President and Head of R&D · Jan 14, 2026